fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Dementia is falling in UK

Written by | 17 Jul 2013

The new study, which was led by Professor Carol Brayne, of the Cambridge Institute of Public Health (CIPH), University of Cambridge, UK, is part of the Medical Research… read more.

Hypertension and increased risk for AD?

Written by | 29 Mar 2013

Major journal reports study findings.  A study in the JAMA Neurology suggests that controlling or preventing risk factors such as hypertension earlier in life may limit or delay the brain… read more.

Use it or lose it in AD

Written by | 11 Mar 2013

Research illuminates a molecular mechanism for why a stimulating environment may protect against Alzheimer’s Disease.

Could obesity make Alzheimer’s worse?

Written by | 11 Feb 2013

World Health Matters – France – by Gary Finnegan – The detrimental effects of obesity are well-documented with public health specialists warning of a tidal wave of diabetes… read more.

‘Second-hand smoke’ increases dementia risk

Written by | 11 Feb 2013

World Health Matters – China – by Gary Finnegan –  A study of nearly 6,000 people in five provinces in China has shown that people exposed to passive… read more.

Hormone therapy within five years of menopause lowers Alzheimer’s risk

Written by | 7 Feb 2013

FDA Highlights by Bruce Sylvester – Women who start hormone therapy within 5 years of menopause onset could reduce their risk of developing Alzheimer’s disease,

Hormone therapy within five years of menopause lowers Alzheimer's risk

Written by | 7 Feb 2013

FDA Highlights by Bruce Sylvester – Women who start hormone therapy within 5 years of menopause onset could reduce their risk of developing Alzheimer’s disease,

World’s largest respiratory genetics study launches on World COPD Day

Written by | 21 Dec 2012

Researchers from the Universities of Nottingham and Leicester are leading the largest ever study of the genetics relating to lung disease.

Alzheimer’s imaging gets the go-ahead

Written by | 14 Dec 2012

by Gary Finnegan – EMA Highlights – The first radiopharmaceutical for positron emission tomography (PET) imaging of β-amyloid neuritic plaque density has been approved by the EMA’s Committee… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.